Biotech boom forecasted for 2024 as industry experts predict a continuation of the recent wave of mergers and acquisitions. Top analysts at Jefferies and Wedbush cite the Bristol Meyers-Karuna deal as a harbinger of more deals soon. MPM's Christiana Bardon identifies a crop of promising biotech companies ripe for acquisition, highlighting the top 10 M&A targets in 2023.